Atara Biotherapeutics, Inc. — Director's Dealing 2017

Jun 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2017-06-08

Reporting Person: Gallagher Carol Giltner (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-08	Common Stock	A	5000	$0.00	Acquired	108374	Direct
2017-06-09	Common Stock	S	1000	$13.15	Disposed	107374	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-08	Non-Qualified Stock Option (Right to Buy)	$13.20	A	21500	Acquired	2027-06-08	Common Stock (21500)	Direct

Footnotes

F1: These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service.

F2: Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016.

F3: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service.